{"id":"vla2001-adolescent-part","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine induces an immune response against the SARS-CoV-2 spike protein, which is a key component of the virus responsible for COVID-19. By expressing the spike protein, the vaccine stimulates the body to produce antibodies and immune cells that can recognize and neutralize the virus. This provides protection against COVID-19 infection.","oneSentence":"VLA2001 is a COVID-19 vaccine that uses a recombinant, replication-incompetent chimpanzee adenovirus vector to express the SARS-CoV-2 spike protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:46.214Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adolescents"}]},"trialDetails":[{"nctId":"NCT04864561","phase":"PHASE3","title":"COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2021-04-26","conditions":"SARS-CoV-2 Virus Infection","enrollment":4034}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VLA2001 - adolescent part","genericName":"VLA2001 - adolescent part","companyName":"Valneva Austria GmbH","companyId":"valneva-austria-gmbh","modality":"Biologic","firstApprovalDate":"","aiSummary":"VLA2001 is a small molecule vaccine being studied for its effectiveness against SARS-CoV-2 virus infection. The VLA2001 adolescent part is a component of the COV-COMPARE study, which compares the immunogenicity of VLA2001 to AZD1222 in individuals of various age groups, including adolescents.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}